NCT04846166|Completed
I-Smads in Periodontitis
Role of Inhibitor SMADs in Stage 3 Grade B Periodontitis Before and After Periodontal Treatment
Loading search results
Role of Inhibitor SMADs in Stage 3 Grade B Periodontitis Before and After Periodontal Treatment
Sponsor study identifier
observational
40
1 country
1
Study Start
August 1, 2019
Actual (reported)Primary Completion
March 1, 2020
Actual (reported)Study Completion
March 1, 2020
Actual (reported)Recently, it has been stated that Smads play an active role in all conditions where transforming growth factor-beta (TGF-β) is involved, including periodontal inflammation. This study aimed to examine the levels of TGF-β and inhibitor Smads in saliva and gingival crevicular fluid (GCF) in patients with Stage 3 Grade B periodontitis before and after non-surgical periodontal treatment. Twenty (20) stage 3 grade B periodontitis and 20 periodontally healthy individuals were included in the study. Clinical periodontal measurements were recorded; periodontitis patients received non-surgical periodontal treatment, and GCF and saliva samples were obtained at baseline and one month after treatment. TGF-β, Smad6, and Smad7 were determined by ELISA.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 1, 2020
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 1, 2019
Actual (reported)March 1, 2020
Actual (reported)March 1, 2020
Actual (reported)April 12, 2021
Actual (reported)April 15, 2021
Actual (reported)TGF-β, Smad6, and Smad7 levels
the levels of TGF-β, Smad6, and Smad7 in gingival crevicular fluid (GCF) and saliva
baseline
TGF-β, Smad6, and Smad7 levels
baseline and 1st month after treatment
probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium
: interdental clinical attachment level (CAL) ≥ 5 mm and PPD ≥ 6 mm on at least two non-adjacent teeth, bone loss involving the middle or apical third of the root radiographically, moderate ridge defect and ≥30% of teeth
1. group (Control): Periodontally and systemically healthy 2. group: Systemically healthy and periodontitis
Figen Öngöz Dede
Ordu, 52100, Turkey (Türkiye)
40 participants (actual enrollment reported by the registry).
First Submitted
April 12, 2021
First Posted
April 15, 2021
Study Start
August 1, 2019
Actual (reported)Microbiome and Proteome Mapping in Periodontitis
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
March 1, 2020
Actual (reported)Study Completion
March 1, 2020
Actual (reported)Last Updated
April 19, 2021
Record last verified: 2021-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: